The Scale Problem: Why We’re Only Now Seeing the Bigger Picture
Here’s what keeps me awake at night about GLP-1 receptor agonists: we’ve been staring at them through a weight-loss telescope for so long that we almost missed everything else happening in the background. This isn’t a complaint about the weight loss benefits, which are genuinely remarkable. It’s about proportion. When a drug class explodes into the cultural consciousness at this magnitude, our measurement instruments tend to align with whatever we noticed first. The metabolic machinery of appetite suppression was obvious, immediate, visible. Everything else got squeezed into the periphery.
What 2025 has revealed is that the GLP-1 story isn’t actually about appetite at all. Or rather, it’s about appetite the way a symphony is about a single violin. The appetite effects are real and profound. But they’re happening alongside something far more complicated: a drug that appears to be fundamentally rewiring how our brains negotiate with desire itself. Understanding this means we have to stop measuring just the weight on the scale and start measuring the architecture of craving.
Cardiovascular Gains in Non-Diabetics: Redefining the Patient Population
The SELECT trial, which ran from late 2023 through 2025 and was published in the New England Journal of Medicine, delivered a finding that should have restructured how we think about semaglutide completely. The study tracked over 17,000 non-diabetic patients with obesity and found that the drug reduced major cardiovascular events by 20 percent. Let that sink in. This wasn’t about blood sugar control. This wasn’t about the downstream effects of weight loss on joint stress or metabolic inflammation, though those matter too. This was a direct cardiovascular protection signal in patients who didn’t have diabetes to begin with.
The implications ripple outward. For decades, pharmaceutical development followed predictable channels: develop a diabetes drug, watch for weight loss, add an obesity indication. The SELECT Trial Results – New England Journal of Medicine essentially inverted that logic. You have patients with obesity but healthy blood sugar. They take semaglutide. Their hearts work better. The mechanism isn’t purely mechanical — it’s not just “they weigh less so their hearts work less hard.” Something about the drug itself appears to be protecting the cardiovascular system independently of weight. By mid-2025, the FDA had already approved once-weekly oral semaglutide specifically for cardiovascular indications, expanding the label beyond its traditional diabetes and obesity uses.
This matters because it tells us we’re dealing with a drug whose effects reach across multiple biological systems at once. The cardiovascular protection might operate through reduced inflammation, through direct effects on blood vessel function, through changes in how the heart processes fuel. We’re still mapping the territory. But the signal is unmistakable.
The Dopamine Connection: Addiction and the Brain’s Reward System
Now we arrive at the finding that genuinely thrilled me when I first read the 2025 data. A research team at the University of Copenhagen published work showing that GLP-1 receptors are present and active in dopaminergic neurons in the nucleus accumbens. This is not a minor detail. The nucleus accumbens is essentially the brain’s reward processing center, where dopamine concentrations modulate desire, motivation, and the anticipatory craving that drives addictive behavior. The discovery that GLP-1 receptors exist in this precise location opened a door that pharmaceutical neuroscience has been trying to unlock for decades.
A concurrent 2025 study published in Nature Medicine tracked 600 patients with alcohol use disorder and found that GLP-1 receptor agonists reduced relapse rates by approximately 40 percent. For context, most evidence-based addiction treatments show relapse reduction in the 20 to 30 percent range over similar timeframes. We’re not talking about marginal improvements here. We’re talking about a drug that might fundamentally alter how the brain processes wanting itself.
The mechanistic picture is becoming clearer. The dopaminergic neurons in the nucleus accumbens use GLP-1 signaling as part of their motivational machinery. When GLP-1 agonists activate these receptors, they appear to dampen the urgency of reward-seeking behavior. It’s not that people stop wanting things. The wanting becomes quieter, more manageable, less tyrannical. For someone with alcohol use disorder, that shift in the volume of craving could be the difference between relapse and recovery.
Scale and Speed: Understanding the Pharmaceutical Transformation
The numbers here deserve careful attention because they reveal something about how medical innovation actually works at scale. Novo Nordisk reported global semaglutide sales exceeding 21 billion dollars in 2024, making it one of the fastest-growing drug classes in pharmaceutical history. To contextualize: that’s roughly equivalent to the annual pharmaceutical revenue of most national drug budgets. The drug went from a niche diabetes medication to a cultural phenomenon in less than five years.
This rapid scaling has consequences, both positive and negative. On the positive side, serious research resources are flowing into understanding the drug’s mechanisms. Universities and pharmaceutical companies are investing heavily in mapping where GLP-1 receptors exist throughout the body and brain. The cardiovascular data from SELECT, the dopamine research from Copenhagen, the addiction studies in Nature Medicine — all of this work is being accelerated by the sheer economic and social interest in understanding semaglutide better. On the negative side, the hype cycle distorts perception. The drug is genuinely transformative for some patient populations. It’s not a panacea. Distinguishing between the two requires sustained skepticism paired with genuine enthusiasm for what the data actually shows.
The Novo Nordisk 2024 Annual Results also reveal something about market concentration. A single drug driving over 21 billion in revenue means one pharmaceutical company now holds extraordinary influence over the future of obesity medicine, addiction treatment, and cardiovascular care. This creates both opportunity and vulnerability. The opportunity lies in directed research investment. The vulnerability lies in consolidating so much around a single mechanism.
What We Still Don’t Know: The Incomprehensible Remains
This is where I get genuinely delighted by the scientific process. For every answer that 2025 has delivered about GLP-1 agonists, the research has revealed three new questions underneath. We know the drug works across multiple organ systems. We don’t fully understand why it works, or why some patients respond dramatically while others show minimal effects. We know GLP-1 receptors exist throughout the body. We don’t have the complete map of every tissue and neuron where they operate, or what all those locations contribute to the overall clinical effect.
The cardiovascular protection signal in non-diabetics is real, but researchers are still debating how much comes from weight loss, how much from direct effects on blood vessel function, how much from anti-inflammatory signaling, and how much from changes in how the heart metabolizes fuel. The addiction data is promising, but longer follow-up studies are needed to determine whether the benefits persist, whether tolerance develops, and whether the mechanism works equally across different types of addiction.
Scientific progress doesn’t resolve mysteries so much as trade them for bigger, more complicated ones. GLP-1 receptor agonists have moved from being a single-indication drug to a multi-system therapeutic with implications spanning cardiology, psychiatry, addiction medicine, and metabolic disease. We’re watching the scientific community zoom out from a weight-loss lens to a whole-body lens. What turns up as that process continues will likely surprise us.
If you’ve been following the semaglutide story and want to dig deeper into the mechanisms, the cardiac data, or the addiction research, I’d genuinely love to hear what aspect fascinates you most. The science here is still being written. Every new paper, every new indication, every new mechanistic insight reshapes how we understand what this drug actually does and who it might help.